You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA406
  • Published:  28 September 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Information about crizotinib
  • 3 Evidence
  • 4 Committee discussion
  • 5 Implementation
  • 6 Recommendations for research
  • 7 Appraisal committee members, guideline representatives and NICE project team

3 Evidence

The appraisal committee considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.


Next page 4 Committee discussion Previous page 2 Information about crizotinib
Back to top